LATEST NEWS

We’re excited to announce our online events, new branding and new website now live!

FIND OUT MORE | 2 Minute read

MOST POPULAR READS

Lack of collaboration the biggest challenge in adopting blockchain, says IBM

READ MORE | 3 Minute Read

Industry’s shift towards large molecules and how to maintain balance

READ MORE | 4 Minute Read

Backend, Baffling and Buzzing: Blockchain

READ MORE | 20 Minute Read

Technology

READ MORE | 7 Minute Read

The future of the pharmaceutical industry

READ MORE | 12 Minute Read

LIFE SCIENCE INTEGRATES INDUSTRY INSIGHTS

Treatment

READ MORE | 5 Minute Read

Technology

READ MORE | 7 minute read

Talent

READ MORE | 5 Minute Read

Tactics

READ MORE | 5 Minute Read

Considering The Patient

READ MORE | 5 Minute Read

Catapults

READ MORE | 5 Minute Read

MARCO MOHWINCKEL INSIGHTS

Marco Mohwinckel: Revolutionising Drug Discover With Big Data And AI

READ MORE | 10 Minute Read

Marco Mohwinckel:
Backend and Buzzing:
Blockchain

READ MORE | 20 Minute Read

Marco Mohwinckel:
The Disruptive Power
of Pharma AI

READ MORE | 10 Minute Read

VISIT OUR INSIGHTS AREAS

WHITE PAPERS

Data Integrity – A Closer Look

Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016...

Navigating Market Access For Cell & Gene Therapy

A substantial number of cell and gene therapies (C&GTs) delivering a cure or at least durable health benefits are expected over the next 5 to 10 years – for example, MIT NEWDIGS researchers estimated that about 40 gene therapies may be approved by the end of 2022.

LATEST NEWS

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on September 1, 2020, at 10 am Helsinki time to elect Cynthia Schwalm as a new board member. The notice to the EGM was...

New Drug for TACTIC-E COVID-19 Trial

Pharmaceutical outsourcing specialist Quay Pharma’s acknowledged expertise in microbial biotherapeutics has played a crucial role in the development of an experimental therapy with the potential to prevent and treat the complications from COVID-19.

INDUSTRY INSIGHTS

Treatment

A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases. 

Technology

With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.

Talent

A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?

Tactics

In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.

ON TWITTER

WHITE PAPERS

Data Integrity – A Closer Look

Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016...

Navigating Market Access For Cell & Gene Therapy

A substantial number of cell and gene therapies (C&GTs) delivering a cure or at least durable health benefits are expected over the next 5 to 10 years – for example, MIT NEWDIGS researchers estimated that about 40 gene therapies may be approved by the end of 2022.

LATEST NEWS

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on September 1, 2020, at 10 am Helsinki time to elect Cynthia Schwalm as a new board member. The notice to the EGM was...

New Drug for TACTIC-E COVID-19 Trial

Pharmaceutical outsourcing specialist Quay Pharma’s acknowledged expertise in microbial biotherapeutics has played a crucial role in the development of an experimental therapy with the potential to prevent and treat the complications from COVID-19.

INDUSTRY INSIGHTS

Treatment

A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases. 

Technology

With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.

Talent

A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?

Tactics

In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.

ON TWITTER

PREVIOUS EVENTS

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.